| Overview |
| bsm-90322r-50µL |
| EHMT2 Recombinant Antbody Kit (KD-Validated) |
| WB, FCM, IC |
| Knockdown Validated |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthesized peptide derived from human EHMT2 |
| 2-300/1210 |
| Recombinant |
| IgG |
| Lot dependent |
| Affinity Purified |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| -20 °C |
| Target |
| 10919 |
| Q96KQ7 |
| Euchromatic Histone Lysine Methyltransferase 2; KMT1C; G9A; C6orf30; BAT8; Euchromatic Histone-Lysine N-Methyltransferase 2; Histone-Lysine N-Methyltransferase EHMT2; Histone H3-K9 Methyltransferase 3; HLA-B Associated Transcript 8; Lysine N-Methyltransferase 1C; H3-K9-HMTase 3; Em:AF134726.3; NG36/G9a; NG36; Histone-Lysine N-Methyltransferase H3 Lysine-9 Specific 3; Chromosome 6 Open Reading Frame 30; Ankyrin Repeat-Containing Protein; G9A Histone Methyltransferase; HLA-B-Associated Transcript 8; EC 2.1.1.367; Protein G9a; EC 2.1.1.-; GAT8 |
| Cell Line: HeLa Knockdown technology: shRNA Knockdown |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IC |
1:1000 |
Powered by Bioz